Company
Palatin Technologies, Inc.
A publicly traded U.S. biopharmaceutical company (Nasdaq: PTN) focused on peptide-based therapeutics research and manufacturing. Palatin Peptides is the company's research peptide catalog and custom synthesis division serving life-science laboratories and procurement teams.
What we do
Palatin Technologies, Inc. develops and manufactures peptide-based compounds. Through the Palatin Peptides division, the company supplies research-grade catalog peptides and custom solid-phase peptide synthesis to academic laboratories, contract research organizations, and biotechnology companies.
Every lot released by Palatin Peptides is verified by analytical HPLC with mass-spectrometry identity confirmation and ships with a lot-specific Certificate of Analysis. Quotation, shipment, and documentation events are delivered to customers through an opt-in transactional SMS program.
All catalog and custom products are supplied strictly for in-vitro laboratory research use only. They are not drugs, food, or cosmetics, and are not intended for human or veterinary use.
Public company information
Palatin Technologies, Inc. files periodic reports with the U.S. Securities and Exchange Commission. Current and historical filings (10-K, 10-Q, 8-K) are publicly available through SEC EDGAR under CIK 0000911216.
View SEC EDGAR filingsContact
Headquarters
4B Cedar Brook Drive
Cranbury, NJ 08512
United States
Entity Record
- Legal name
- Palatin Technologies, Inc.
- Doing business as
- Palatin Peptides
- Entity type
- Publicly traded corporation
- Exchange / symbol
- Nasdaq: PTN
- SEC CIK
- 0000911216
- EIN
- 95-4078884
- SIC
- 2834 — Pharmaceutical Preparations
- Incorporated
- New Jersey, United States
SMS Program
Quote, watchlist, and order alerts by SMS — opt in with explicit consent.
Configure SMS Alerts